Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients

Core Insights - Kairos Pharma Ltd. has announced a collaboration with PreCheck Health Services to develop companion biomarkers for its cancer therapy ENV105, targeting prostate and lung cancers [1][10] - The partnership aims to enhance patient screening and therapy monitoring in ongoing Phase 1 and Phase 2 clinical trials [1][2] Company Overview - Kairos Pharma is a clinical-stage biopharmaceutical company focused on oncology therapeutics, utilizing structural biology to address drug resistance and immune suppression [8] - The company is based in Los Angeles, California, and is committed to improving patient outcomes through innovative treatment options [8] Collaboration Details - The collaboration will utilize advanced molecular diagnostics to validate and develop biomarkers identified in previous clinical trials, aiming for a personalized approach to cancer care [2][6] - PreCheck Health Services will analyze biopsy tissues and circulating tumor cells from patients in ongoing trials, including a Phase 2 trial for prostate cancer and a Phase 1 trial for lung cancer [2][4] Clinical Trials - Two key clinical trials are highlighted: - NCT05401110, a Phase 1 trial for EGFR-driven lung cancer patients resistant to osimertinib, focusing on gene expression profiling [4] - NCT05534646, a Phase 2 trial for castrate-resistant prostate cancer patients, concentrating on profiling circulating tumor cells and tumor biopsies [4][5] Companion Diagnostics Development - A significant outcome of the partnership is the development of a companion diagnostic for ENV105, which will include a three-gene PCR analysis to predict patient responses [6] - This diagnostic aims for FDA approval to guide patient selection for Phase 3 clinical trials [6] Technological Integration - The collaboration will leverage PreCheck's SolidTumorCheck+ platform for gene expression profiling of tumor biopsies, potentially leading to non-invasive liquid biopsy tests for future patient screening [3][7] - The integration of biomarkers and liquid biopsy technologies is expected to enhance treatment precision and improve patient outcomes [7][10]